Clinical trial · people
Tesamorelin drug levels unaffected by age, size, race or HIV status
Checked against the paper Clinical trialPublished by PepVault
The takeaway
This paper describes how tesamorelin moves through the body and found no difference by HIV status, age, body size or race, but it tells you nothing about its effects.
- Kind
- Clinical trial
- Studied in
- People
- Number studied
- 38
- Published
- 2015
- Journal
- Clin Pharmacokinet
What they tested
The team set out to describe how tesamorelin is absorbed and cleared from the body in people with HIV and in healthy people, and what factors change that.
How the study was done
A phase I analysis of 38 people with HIV and healthy volunteers who got 1 or 2 mg of tesamorelin under the skin each day for 14 days. The researchers built a computer model of blood drug levels over time and checked it against the data.

What they found
Plasma clearance, how fast the drug is removed from the blood, was 1,060 L/h, and it varied between people by 33.6%. Volume of distribution, how widely the drug spreads in the body, was 200 L (17.7% variation). Age, body size, race and health status were not linked to how the body handled tesamorelin within the ranges studied. The share of the dose taken up by one of its two absorption routes was 13.1% higher on day 14 than on day 1.
What it doesn’t show
This was a small, 14-day study that looked only at drug levels in the blood, not at effects on fat, growth hormone or health. The factors tested were only checked within the range of people enrolled.
The paper
González-Sales et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet. 2015.
The compound
More studies on Tesamorelin
- Tesamorelin: visceral fat down 27.71 cm² in HIV lipodystrophyMeta-analysis · people · 2026
- Tesamorelin shifted liver gene activity in HIV-related fatty liverRandomized trial · people · 2020
- Tesamorelin: denser, larger trunk muscles at 26 weeks in HIVRandomized trial · people · 2019
- Tesamorelin: no change in glucose control in type 2 diabetesRandomized trial · people · 2017
- Tesamorelin cut visceral and liver fat over 6 months in HIV patientsRandomized trial · people · 2014
- Tesamorelin had little effect on simvastatin and ritonavir levelsRandomized trial · people · 2013
- Every study on Tesamorelin
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.